Rafael Garcia-Cortes, MD
Advanced Heart Failure and Transplant Cardiology · Indianapolis, INNPI 1013145986
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,220 of the $101,305 with a category attached, or 82.1%. 6 manufacturers reported payments, led by Pfizer at 37.0% of the total.
Across 86 payments — averaging $1177.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$38K
- E.r. Squibb & Sons, L.L.C.$31K
- Novartis$31K
- Abbott$1K
- EKOS Corporation$111
- Medtronic$14
What the payments were for
- Consulting fees$7,0257%
- Speaking & faculty fees$83,22082%
- Travel & lodging$7,8608%
- Food & beverage$3,2003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 22 | $37,519 |
| E.r. Squibb & Sons, L.L.C. | 23 | $31,281 |
| Novartis | 26 | $31,262 |
| Abbott | 13 | $1,118 |
| EKOS Corporation | 1 | $111 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$37,425
- ENTRESTO$30,993
- CAMZYOS$29,995
- VYNDAMAX$466
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$335
- CARDIOMEMS$140
- HeartMate 3 Left Ventricular Dev$127
- Mitra Clip system$120
- EKOSONIC$111
How this compares
$101,305 in reported general payments places this provider in the 80th percentile of 20 advanced heart failure and transplant cardiology providers in Indiana.
See all advanced heart failure and transplant cardiology providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 12 | $353,652 |
| EntrestoSacubitril/Valsartan | 210 | $301,393 |
| JardianceEmpagliflozin | 185 | $234,275 |
| EliquisApixaban | 102 | $128,187 |
| CamzyosMavacamten | 14 | $118,165 |
| FarxigaDapagliflozin Propanediol | 26 | $36,843 |
| XareltoRivaroxaban | 14 | $15,748 |
| Sirolimus | 27 | $9,978 |
| Tacrolimus | 36 | $5,293 |
| Ezetimibe | 143 | $3,181 |
| Metoprolol Succinate | 240 | $3,037 |
| Atorvastatin Calcium | 306 | $2,498 |
| Mycophenolate Mofetil | 15 | $2,016 |
| Torsemide | 66 | $1,988 |
| Cyclosporine ModifiedCyclosporine, Modified | 11 | $1,763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $37,519 | $481,839114 claims |
| NovartisEntresto | $31,262 | $301,393210 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $31,281 | $118,16514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 20 advanced heart failure and transplant cardiology providers in Indiana.
Other advanced heart failure and transplant cardiology in Indianapolis
- Sasikanth AdigopulaIndianapolis$310K
- Ashwin RavichandranIndianapolis$284K
- Amit PatelIndianapolis$41K
- Sunit-Preet ChaudhryIndianapolis$27K
- Radha KannegantiIndianapolis$18K
- Mary WalshIndianapolis$17K
- Bhavana Siddegowda-BangaloreIndianapolis$5K
- Sangita SudharshanIndianapolis$2K
- Muhamad SafiiaIndianapolis$2K
- Philip KirlinIndianapolis$967
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.